ClinicalTrials.gg
CompletedNCT02644018ACCORDUpdated Jun 9, 2016

Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.

A Phase 3 interventional study of Imidazolyl ethanamide pentandioic acid and placebo in Common Cold and Influenza, sponsored by Valenta Pharm JSC. Completed at 13 sites in Russian Federation. Open to participants aged 3 Years to 6 Years. Per ClinicalTrials.gov, last updated 2016-06-09.

Sponsored by Valenta Pharm JSC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
3 Years to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Common Cold with a site in Russian Federation — 1 open to participants now, 1 under way, none of them phase 3. Common Cold · Russian Federation.

Enrollment
8th of 11
190 · median 250
Started
2016
the only one that year
Phase 3
8 of 13
none open now
Registered
3rd of 13
by date
Lead sponsor
9 of 13
Valenta Pharm JSC

Among the 13 studies in Common Cold with a site in Russian Federation, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2016, is one of 8 in phase 3, and was the 3rd registered.

Common Cold

219 studies on the registry are indexed under Common Cold; 23 are open to participants now.

Browse Common Cold studies →

Open to participants now

1 of the 13 studies in Common Cold with a site in Russian Federation is open now. Recruiting first, the newest first:

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 14 Common Cold studies recruiting now, 4 (29%) set no upper age limit and 9 (64%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 3 Years to 6 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Common Cold with a site in Russian Federation, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether Ingavirin ® dosed 30 mg daily is effective and safe in the treatment of influenza and other acute respiratory viral infections in the course of standard therapy in 3-6 years old patients.

03

Conditions studied

  • Common Cold
  • Influenza

Keywords

  • Ingavirin
  • Common Cold
  • Influenza
  • Acute Respiratory Viral Infections
  • pediatric clinical trial
  • Imidazolyl ethanamide pentandioic acid
04

Who can participate

Ages eligible
3 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The form signed by the patient's parent/adoptive parent to participate in the clinical study.
  • Male and female patients aged 3-6.
  • Patients with moderate course of influenza or other acute respiratory viral infections.
  • Patients with clinically diagnosed influenza or other ARVI based on the body temperature > 37,5 ° C, not less than 1 of the following other symptoms of intoxication and not less than 1 of the following of catarrhal symptoms:

    • Intoxication symptoms: headache, malaise, myalgia, pain in the eyeballs;
    • Catarrhal symptoms: sore throat, rhinorrhea, cough, nasal congestion.
  • Established diagnosis J06.9, J10, J11, in accordance with ICD-10.
  • Uncomplicated course of influenza and other ARVI.
  • Interval between onset of symptoms and enrollment to the study of not more than 36 hours.

Exclusion criteria

Exclusion Criteria:

  • Complicated course of influenza and other acute respiratory viral infections.
  • Treatment with antiviral drugs (antivirals, interferons and interferon inducers), drugs with immunomodulatory effects or antibiotics with systemic and local action within 14 days prior to the screening visit.
  • Severe influenza or other ARVI with symptoms of cardiovascular disease, and other symptoms of infectious-toxic shock, and meningoencephalitic syndromes.
  • Signs of primary viral pneumonia development (presence of two or more of the following symptoms): shortness of breath, chest pain when coughing, systemic cyanosis, dullness of percussion sound at symmetrical assessment of the upper and lower parts of the lungs.
  • Infectious diseases within the last week prior to enrollment.
  • "RRI children" (incidence of ARVI within the last 12 months is 6 times or more).
  • Asthma history.
  • History of increased seizure activity.
  • Severe decompensated or unstable medical or psychiatric conditions (any diseases or conditions that threaten the life of the patient or worsen the patient's prognosis and also make it impossible to conduct a clinical study in the patient).
  • Cancer, infection, tuberculosis, including those in history.
  • to imidazolyl ethanamide pentandioic acid and/or of Ingavirin product.
  • Diabetes, lactose intolerance, lactase deficiency, glucose-galactose malabsorption, deficiency of sucrase/isomaltase, fructose intolerance, hereditary glucose malabsorption, deficiency of glucose-6-phosphate dehydrogenase.
  • Participation of the patient in any other clinical trial within the last 90 days prior to enrollment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
190 participants (actual)

Study arms

  • Experimental
    Ingavirin

    Ingavirin (Imidazolyl ethanamide pentandioic acid), capsules 30 mg daily for 5 days. The contents of one capsule of Ingavirin, capsules 30 mg should be dissolved in 50-70 ml of water at room temperature or apple juice at room temperature with mandatory stirring for 20 seconds and administered orally 1 time a day regardless of the meal.

    Drug: Imidazolyl ethanamide pentandioic acid

  • Placebo comparator
    Placebo

    Placebo, capsules daily for 5 days. The contents of one capsule of placebo should be dissolved in 50-70 ml of water at room temperature or apple juice at room temperature with mandatory stirring for 20 seconds and administered orally 1 time a day regardless of the meal.

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Time to decrease in the Influenza and Other ARVI Severity Scale score to 2 points with no more than 1 point at individual subscales and normalization of body temperature

    Temperature normalization means establishment of body temperature below 37 ° C without raising thereafter till 5 days after the treatment start.

    Time frame: 5 days

Secondary outcomes

  1. Time to decrease in the Influenza and Other ARVI Severity Scale score to 0 points

    Time frame: 5 days

  2. Average score at the Influenza and Other ARVI Severity Scale by the 1st, 2nd, 3rd, 4th and 5th days after the start of treatment

    Time frame: Within 6 days from the start of treatment

  3. The area under the "Influenza and Other ARVI Severity Scale score - time" curve by the 5th day after the start of treatment

    Time frame: 5 days

  4. Time to normalization of body temperature from the start of treatment, measured in hours

    Temperature normalization means establishment of body temperature below 37°C without raising thereafter till 5 days after the treatment start

    Time frame: 5 days

  5. The average body temperature by the1st, 2nd, 3rd, 4th and 5th days after the start of treatment

    Time frame: 5 days

  6. The percentage of patients with normalization of body temperature by the 1st, 2nd, 3rd, 4th and 5th days after the start of treatment

    Time frame: 5 days

  7. The area under the "temperature-time" curve by the 5th day after the start of treatment

    Time frame: 5 days

  8. The percentage of patients with complications of influenza and other ARVI developed over the period from the 1st to the 6th and from the 1st to 14th day after the start of treatment

    Time frame: 14 days

  9. The percentage of patients with severe complications of influenza and other ARVI that have developed over the period from the 1st to the 6th and from the 1st to 14th day after the start of treatment

    Time frame: 14 days

  10. Time to onset of complications of influenza and other ARVI from the start of treatment

    Time frame: 14 days

  11. Assessment of adverse events (AEs) and serious adverse events (SAEs)

    Assessment of adverse events (AEs) and serious adverse events (SAEs) by means of - * Portion of patients who developed one or more SAE during the study * Portion of patients who developed one or more AE during the study * Portion of patients who developed one or more severe AE during the study * Portion of patients who developed one or more AE with definite relationship to the investigational product/ placebo during the study * Portion of patients who developed one or more AE with definite or probable relationship to the investigational product/ placebo during the study

    Time frame: 14 days

07

Study locations

13 sites
  • GBOU VPO "Kazan State Medical University" of Ministry of Health of Russian Federation
    Kazan, Russian Federation
  • GBOU VPO "Krasnoyarsk State Medical University n.a.n V.F. Voyno-Yasenetskogo" of Ministry of Health of Russian Federation
    Krasnoyarsk, Russian Federation
  • FGBU "Scientific center of children health" of the Ministry of Health of Russian Federation
    Moscow, Russian Federation
  • I.M. Sechenov First Moscow State Medical University
    Moscow, Russian Federation
  • Moscow Budgetary Public Health Facility "Infectious clinical hospital #1" of Moscow City Health Department
    Moscow, Russian Federation
  • GBOU VPO "Novosibirsk State Medical University of Ministry of Health of Russian Federation"
    Novosibirsk, Russian Federation
  • Children's city outpatients clinic № 5
    Perm, Russian Federation
  • Children's city outpatients clinic № 4
    Rostov-na-Donu, Russian Federation
  • GBOU VPO "Rostov State Medical University" of Ministry of Health of Russian Federation
    Rostov-na-Donu, Russian Federation
  • FGBU "Scientific Research Institute of Children's Infections, Federal Biomedical Agency"
    Saint-Petersburg, Russian Federation
  • FGBOU VPO "Mordov State University n.a. N.P. Ogarev"
    Saransk, Russian Federation
  • GBOU VPO "Siberia State Medcial University" of Ministry of Health of Russian Federation
    Tomsk, Russian Federation
  • GBOU VPO "Yaroslavl State Medical University" of Ministry of Health of Russian Federation
    Yaroslavl, Russian Federation
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2016, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2015
First posted
Dec 31, 2015
Start
Jan 2016
Primary completionActual
May 2016
CompletionActual
May 2016
Last update
Jun 9, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02644018
Lead sponsor
Valenta Pharm JSC
Collaborators
Atlant Clinical Ltd.
Responsible party
Sponsor
First posted
Dec 31, 2015
Start date
Jan 2016
Primary completion
May 2016
Completion
May 2016
Last update
Jun 9, 2016

Study contacts

Ekaterina Zakharova, MD, PhD
study director · Valenta Pharm JSC
Yuriy V. Lobzin, MD, PhD
principal investigator · Scientific Research Institute of Children's Infections, Federal Biomedical Agency, Saint-Petersburg, Russian Federation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pentanedioic acid imidazolyl ethanamide

Start the discussion